Seagen
Pays vs peer median
×1.48
+48% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | Anti-Orexin-101 | Passage Bio | Migraine | phase_3 | $353M | $2.5B |
| 2024 | Anti-EphA2-501 | Immunocore | HCC | discovery | $18M | $263M |
| 2023 | bladder | Astellas Pharma | bladder | approved | — | $800M |
| 2023 | TDP-43 | Longboard Pharmaceuticals | Alzheimer's Disease | phase_3 | $1.1B | $6.6B |
| 2022 | ROS1-101 | Viracta Therapeutics | T-cell Lymphoma | phase_3 | $806M | $3.3B |
| 2021 | SV2A | Axsome Therapeutics | OCD | discovery | $13M | $154M |
| 2020 | GABA-A-stat | Karuna Therapeutics | Migraine | approved | $543M | $2.1B |
How this is computed
For each Seagen deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.479, clamped to [0.7, 1.5].